NEW
YORK, Oct. 24, 2022 /PRNewswire/ -- Delcath
Systems, Inc. (Nasdaq: DCTH), an interventional oncology company
focused on the treatment of primary and metastatic cancers of the
liver, announced today it will host a conference call on
November 8, 2022, at 8:30 AM Eastern Time to discuss results for its
third quarter ended September 30,
2022.
Conference Call Information
To participate in this event, dial approximately 5 to 10 minutes
before the beginning of the call.
Event Date: Tuesday, November 8,
2022
Time: 8:30 AM Eastern Time
Participant Numbers: Toll Free: 1-844-836-8745
International: 1-412-317-6797
Webcast: https://app.webinar.net/X9na2DKgekK
CONFERENCE REPLAY
US Toll
Free:
|
1-877-344-7529
|
International
Toll:
|
1-412-317-0088
|
Replay Access
Code:
|
5753543
|
End Date:
|
November 15,
2022
|
About Delcath Systems, Inc.
Delcath Systems, Inc. is an interventional oncology company
focused on the treatment of primary and metastatic liver cancers.
The Company's proprietary percutaneous hepatic perfusion (PHP)
system is designed to administer high-dose chemotherapy to the
liver while controlling systemic exposure and associated side
effects. In the United States, the
PHP system is being developed under the tradename
HEPZATOTM KIT (melphalan hydrochloride for
injection/hepatic delivery system), or HEPZATO, for the treatment
of patients with unresectable hepatic-dominant metastatic ocular
melanoma (mOM), also known as metastatic uveal melanoma (mUM) and
is considered a combination drug and device product regulated by
the United States Food and Drug Administration (FDA).
In Europe, the PHP system is
now regulated as a Class lll medical device and is approved for
sale under the trade name CHEMOSAT Hepatic Delivery System for
Melphalan, or CHEMOSAT, where it has been used at major medical
centers to treat a wide range of cancers of the liver.
Safe Harbor / Forward-Looking Statements
The Private Securities Litigation Reform Act of 1995 provides a
safe harbor for forward-looking statements made by the Company or
on its behalf. This news release contains forward-looking
statements, which are subject to certain risks and uncertainties
that can cause actual results to differ materially from those
described, in particular, the expected uses of the proceeds from
the Private Placement. Factors that may cause such differences
include, but are not limited to, uncertainties relating to: the
timing and results of the Company's clinical trials, including
without limitation the mOM and ICC clinical trial programs, as well
as the receipt of additional data and the performance of additional
analyses with respect to the mOM clinical trial, our determination
whether to continue the ICC clinical trial program or to focus on
other alternative indications, and timely monitoring and treatment
of patients in the global Phase 3 mOM clinical trial and the impact
of the COVID-19 pandemic on the completion of our clinical trials;
the impact of the presentations at major medical conferences and
future clinical results consistent with the data presented;
approval of Individual Funding Requests for reimbursement of the
CHEMOSAT procedure; the impact, if any, of ZE reimbursement on
potential CHEMOSAT product use and sales in Germany; clinical adoption, use and resulting
sales, if any, for the CHEMOSAT system to deliver and filter
melphalan in Europe including the
key markets of Germany and the UK;
the Company's ability to successfully commercialize the HEPZATO
KIT/CHEMOSAT system and the potential of the HEPZATO KIT/CHEMOSAT
system as a treatment for patients with primary and metastatic
disease in the liver; our ability to obtain reimbursement for the
CHEMOSAT system in various markets; approval of the current or
future HEPZATO KIT/CHEMOSAT system for delivery and filtration of
melphalan or other chemotherapeutic agents for various indications
in the U.S. and/or in foreign markets; actions by the FDA or
foreign regulatory agencies; the Company's ability to successfully
enter into strategic partnership and distribution arrangements in
foreign markets and the timing and revenue, if any, of the same;
uncertainties relating to the timing and results of research and
development projects; and uncertainties regarding the Company's
ability to obtain financial and other resources for any research,
development, clinical trials and commercialization activities.
These factors, and others, are discussed from time to time in our
filings with the Securities and Exchange Commission. You should not
place undue reliance on these forward-looking statements, which
speak only as of the date they are made. We undertake no obligation
to publicly update or revise these forward-looking statements to
reflect events or circumstances after the date they are made.
Investor Relations Contact:
Ben Shamsian
Lytham
Partners
646-829-9701
shamsian@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/delcath-systems-to-host-third-quarter-2022-results-301657471.html
SOURCE Delcath Systems, Inc.